CA2200869A1 - Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs - Google Patents

Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs

Info

Publication number
CA2200869A1
CA2200869A1 CA002200869A CA2200869A CA2200869A1 CA 2200869 A1 CA2200869 A1 CA 2200869A1 CA 002200869 A CA002200869 A CA 002200869A CA 2200869 A CA2200869 A CA 2200869A CA 2200869 A1 CA2200869 A1 CA 2200869A1
Authority
CA
Canada
Prior art keywords
vector
administration
adenoviral
administered
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002200869A
Other languages
English (en)
Inventor
Bruce C. Trapnell
Soonpin Yei
Allan Mcclelland
Michael Kaleko
Theodore Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Therapy Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2200869A1 publication Critical patent/CA2200869A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention est une méthode de traitement de thérapie génique d'un hôte qui comporte les opérations suivantes : a) administration concomitante à l'hôte i) d'un vecteur adénoviral comportant au moins une séquence d'ADN codant un agent thérapeutique et ii) un agent immunosuppresseur, b) discontinuation de l'administration du vecteur adénoviral et de l'agent immunosuppresseur cités, et c) reprise au moins une fois de l'administration du vecteur adénoviral et de l'agent immunosuppresseur. La répétition du traitement consistant à administrer un vecteur adénoviral et un agent immunosuppresseur permet d'assurer un codage continu de l'agent thérapeutique par une séquence d'ADN au moins ou d'accentuer ce codage.
CA002200869A 1994-10-19 1995-10-19 Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs Abandoned CA2200869A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32567994A 1994-10-19 1994-10-19
US08/325,679 1994-10-19
US47848295A 1995-06-07 1995-06-07
US08/478,482 1995-06-07

Publications (1)

Publication Number Publication Date
CA2200869A1 true CA2200869A1 (fr) 1996-05-02

Family

ID=26985040

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002200869A Abandoned CA2200869A1 (fr) 1994-10-19 1995-10-19 Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs

Country Status (4)

Country Link
EP (1) EP0804076A4 (fr)
JP (1) JPH10507758A (fr)
CA (1) CA2200869A1 (fr)
WO (1) WO1996012406A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
CA2213439A1 (fr) * 1995-02-24 1996-08-29 The Trustees Of The University Of Pennsylvania Methodes et compositions pour l'administration de vecteurs de therapie genique
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
WO1997030167A1 (fr) * 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Procede de traitement des troubles du foie
US6211160B1 (en) * 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
JP2001509168A (ja) 1997-01-29 2001-07-10 コーネル リサーチ ファウンデーション、インコーポレイティッド 血管新生を誘導するためのアデノウイルスベクターの多部位送達
US5985824A (en) * 1997-02-27 1999-11-16 Genzyme Corporation Methods and compositions for treating cystic fibrosis
DE19711803A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung mit 15-Deoxyspergualin
CN1331602A (zh) * 1998-09-21 2002-01-16 遗传研究所有限公司 负调节针对医用蛋白的免疫反应的方法
WO2000029033A2 (fr) * 1998-11-17 2000-05-25 The General Hospital Corporation Technique d'apport de vecteurs genetiques
CA2395544A1 (fr) * 1999-12-28 2001-07-05 Novartis Ag Procede de mise en oeuvre d'une expression persistante de transgenes
US20020014242A1 (en) 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
EP1435776A4 (fr) 2001-09-24 2006-01-25 Univ Pittsburgh Vaccin anticancereux, methodes diagnostiques et reactifs
PL209133B1 (pl) 2001-11-21 2011-07-29 Univ Pennsylvania Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie
EP1944043A1 (fr) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation.
BRPI0417451A (pt) * 2003-12-10 2007-04-10 Canji Inc método de tratar um tumor resistente a interferon
WO2005086922A2 (fr) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Adenovirus oncolytique dote de genes therapeutiques
PT1809321E (pt) 2004-10-08 2012-05-17 Us Gov Health & Human Serv Imunoterapia adotiva com sobrevivência aumentada de linfócitos
WO2007044033A2 (fr) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Récepteur non restreint par le cmh cloné de l'antigène spécifique de tumeur muc1 pour applications thérapeutiques et diagnostiques
KR101662574B1 (ko) 2007-11-28 2016-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
CN102131920B (zh) 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
CA2716928C (fr) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Adenovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
WO2010011994A2 (fr) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides et leurs utilisations
WO2010051367A1 (fr) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-43, -45, -48, -49 et –50 et leurs utilisations
CN102575232B (zh) 2009-05-29 2015-07-22 宾夕法尼亚大学托管会 猿腺病毒41及其应用
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
US9289477B2 (en) 2011-04-29 2016-03-22 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
CA2873509A1 (fr) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Adenovirus simiens de la sous-famille e a1302, a1320, a1331 et a1337 et leurs utilisations
EA201592106A3 (ru) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. Локальное сопутствующее введение толерогенных синтетических наноносителей для снижения гиперчувствительности типа i и гиперчувствительности типа iv
DK3010519T3 (en) 2013-06-18 2021-05-17 Dnatrix Inc Oncolytic adenovirus for use in a treatment of brain cancer
WO2016037163A1 (fr) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Procédés et compositions pour atténuer des réponses immunitaires contre des vecteurs de transfert viraux pour la thérapie génique
CN109152342A (zh) * 2016-05-12 2019-01-04 布赖恩.P.汉利 Crispr和其他基因疗法安全递送到人类和动物中的大部分体细胞
AU2018205496A1 (en) * 2017-01-07 2019-07-25 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
AU2020265215A1 (en) * 2019-04-28 2021-11-18 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232706T2 (de) * 1991-05-01 2002-11-28 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen

Also Published As

Publication number Publication date
JPH10507758A (ja) 1998-07-28
EP0804076A4 (fr) 1998-10-21
EP0804076A1 (fr) 1997-11-05
WO1996012406A1 (fr) 1996-05-02

Similar Documents

Publication Publication Date Title
CA2200869A1 (fr) Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
WO1996012406A9 (fr) Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
EP0710288B1 (fr) Vecteurs adenoviraux pour le traitement de l'hemophilie
US5872154A (en) Method of reducing an immune response to a recombinant adenovirus
Christ et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response
JP3565859B2 (ja) 改良されたアデノウイルスおよびその使用法
AU697022B2 (en) Methods and compositions for administering gene therapy vectors
Varnavski et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity
CA2239366A1 (fr) Generation de vecteurs adenoviraux a mediation de recombinase
JP2004500880A (ja) 肝臓特異的な遺伝子発現カセット、及びその使用法
US6596270B2 (en) Methods of administering adenoviral vectors
US6372208B1 (en) Method of reducing an immune response to a recombinant virus
US6251957B1 (en) Method of reducing an immune response to a recombinant virus
SK282235B6 (sk) Lieková kombinácia na transfekciu a expresiu exogénov in vivo alebo ex vivo
WO1997039776A9 (fr) Therapie genique reposant sur l'administration conjointe et repetee d'adenovirus et d'agents immunosuppresseurs
Fleury* et al. Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial inflammation compared with first-generation adenovirus vectors
WO1997039776A1 (fr) Therapie genique reposant sur l'administration conjointe et repetee d'adenovirus et d'agents immunosuppresseurs
WO2005027711A2 (fr) Vecteurs d'adenovirus a capside modifiee et methodes d'utilisation
US20020144302A1 (en) Novel constructs and vectors for the targeted and inducible expression of genes
US6132989A (en) Methods and compositions for enhanced stability of non-adenoviral DNA
NZ527645A (en) Method of enhancing delivery of a therapeutic nucleic acid
AU2002237910A1 (en) Method of enhancing delivery of a therapeutic nucleic acid
WO2003024384A2 (fr) Procedes ameliores de traitement par vecteurs viraux
Lillicrap Helper-dependent Adenoviral Vectors Mediate Therapeutic Factor VIII Expression for Several Months with Minimal Accompanying Toxicity in a Canine Model of Severe Hemophilia A
Tinlin et al. Sustained phenotypic correction of canine hemophilia A using an

Legal Events

Date Code Title Description
FZDE Dead